Histopathological investigation of glioblastomas resected under bevacizumab treatment-Reference-Cited by-同舟云学术

Histopathological investigation of glioblastomas resected under bevacizumab treatment

Published:2016-05-17 Issue:32 Volume:7 Page:52423-52435
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Tamura Ryota¹,Tanaka Toshihide²,Miyake Keisuke³,Tabei Yusuke⁴,Ohara Kentaro⁵,Sampetrean Oltea⁶,Kono Maya¹,Mizutani Katsuhiro¹,Yamamoto Yohei²,Murayama Yuichi⁷,Tamiya Takashi³,Yoshida Kazunari¹,Sasaki Hikaru¹

Affiliation:

1. Department of Neurosurgery, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

2. Department of Neurosurgery, Jikei University Kashiwa Hospital, Kashiwashita, Kashiwa-shi, Chiba, Japan

3. Department of Neurosurgery, Kagawa University Hospital, Ikedo, Mituki-cho, Kita-gun, Kagawa, Japan

4. Department of Neurosurgery, Japan Red Cross Medical Center, Hiroo, Shibuya-ku, Tokyo, Japan

5. Division of Diagnostic Pathology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

6. Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

7. Department of Neurosurgery, Jikei University Hospital, Nishishinbashi, Minato-ku, Tokyo, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;Brain Tumor Pathology;2024-04

2. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma;Journal of Neuro-Oncology;2024-01-31

3. Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications;Oncology Research;2024

4. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress;Signal Transduction and Targeted Therapy;2023-10-20

5. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;2023-10-06